Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.

MLA

Kulkarni, Diptee, et al. “Pyrexia in Dabrafenib-Treated Melanoma Patients Is Not Associated with Common Genetic Variation or HLA Polymorphisms.” Pharmacogenomics, vol. 17, no. 5, Apr. 2016, pp. 459–62. EBSCOhost, https://doi.org/10.2217/pgs.16.4.

APA

Kulkarni, D., Song, K., Briley, L., King, K., Dabrowski, C., Mookerjee, B., Legos, J., & Spraggs, C. (2016). Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms. Pharmacogenomics, 17(5), 459–462. https://doi.org/10.2217/pgs.16.4

Chicago

Kulkarni, Diptee, Kijoung Song, Linda Briley, Karen King, Christine Dabrowski, Bijoyesh Mookerjee, Jeff Legos, and Colin Spraggs. 2016. “Pyrexia in Dabrafenib-Treated Melanoma Patients Is Not Associated with Common Genetic Variation or HLA Polymorphisms.” Pharmacogenomics 17 (5): 459–62. doi:10.2217/pgs.16.4.